Basal Cell Carcinoma Pipeline 2024 | Pellepharm, Medc Biopharma Corporation, Aiviva Biopharma, Mediwound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma

(MENAFN- GetNews)

DelveInsight's,
“Basal Cell Carcinoma Pipeline Insight 2024”
report provides comprehensive insights about
25+ companies and 25+ pipeline drugs
in Basal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Basal Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Basal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Basal Cell Carcinoma Pipeline Report

• July 2024:- Sol-Gel Technologies, Ltd.- A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome. The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.
• June 2024:- Biofrontera Bioscience GmbH- The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for superficial basal cell carcinoma (BCC).
• DelveInsight's Basal Cell Carcinoma Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Basal Cell Carcinoma treatment.
• The leading Basal Cell Carcinoma Companies such as PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
• Promising Basal Cell Carcinoma Therapies such as BO-112, SP-002, Vismodegib, Nivolumab, Ipilimumab, Relatlimab, Vismodegib, and others.

Stay informed about the cutting-edge advancements in Basal Cell Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Basal Cell Carcinoma Clinical Trials Assessment

Basal Cell Carcinoma Emerging Drugs

• Patidegib: PellePharm

Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.

• AIV001: AiViva BioPharma

AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.

Learn more about Basal Cell Carcinoma Drugs Opportunities in our groundbreaking Basal Cell Carcinoma Research and development projects @ Basal Cell Carcinoma Unmet Needs

Basal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Basal Cell Carcinoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Discover the latest advancements in Basal Cell Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Basal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Basal Cell Carcinoma Pipeline Report

• Coverage- Global
• Basal Cell Carcinoma Companies- PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
• Basal Cell Carcinoma Therapies- BO-112, SP-002, Vismodegib, Nivolumab, Ipilimumab, Relatlimab, Vismodegib, and others.
• Basal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Basal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Basal Cell Carcinoma Pipeline on our website @ Basal Cell Carcinoma Emerging Drugs and Companies

Table of Content